Zepbound’s label describes a timing pattern for nausea, vomiting and diarrhea, rather than every digestive symptom or every patient. The label's own words are that most nausea, vomiting and diarrhea events “occurred during dose escalation and decreased over time” [1]. This page summarizes common reactions and important warnings. The stomach symptoms in detail, rate by rate, are in does Zepbound cause constipation.
The most common Zepbound side effects are digestive
Commonly reported digestive reactions on Zepbound include nausea, diarrhea, vomiting and constipation. After those come injection-site reactions, tiredness, allergic-type reactions, burping, hair loss and reflux [1]. The table shows how often each one happened in the label's two weight-loss trials, by dose, against placebo.
| Side effect | Placebo | 5 mg | 10 mg | 15 mg |
|---|---|---|---|---|
| Any digestive side effect | 30% | 56% | 56% | 56% |
| Nausea | 8% | 25% | 29% | 28% |
| Diarrhea | 8% | 19% | 21% | 23% |
| Vomiting | 2% | 8% | 11% | 13% |
| Constipation | 5% | 17% | 14% | 11% |
| Injection-site reactions | 2% | 6% | 8% | 8% |
| Fatigue | 3% | 5% | 6% | 7% |
| Allergic-type (hypersensitivity) reactions | 3% | 5% | 5% | 5% |
| Burping (eructation) | 1% | 4% | 5% | 5% |
| Hair loss | 1% | 5% | 4% | 5% |
| Reflux (GERD) | 2% | 4% | 4% | 5% |
| Dizziness | 2% | 4% | 5% | 4% |
| Low blood pressure | 0% | 1% | 1% | 2% |
Pool of two weight-reduction trials (placebo 958, 5 mg 630, 10 mg 948, 15 mg 941 people) [1]. Stomach pain, indigestion, gas and bloating are also on the label; the full digestive breakdown is in does Zepbound cause constipation.
The label describes a pattern, not a fixed symptom timeline
The label does not establish a fixed number of days for an individual’s symptoms. What it does say is that most nausea, vomiting and diarrhea happened “during dose escalation and decreased over time” [1]. That statement concerns three named symptoms across trial participants. It does not establish how long constipation, fatigue or a new symptom will last, or mean that worsening symptoms should be ignored.
The people who stopped Zepbound because of side effects mostly did so early. The label says “the majority of patients who discontinued ZEPBOUND due to adverse reactions did so during the first few months of treatment due to gastrointestinal adverse reactions” [1]. How the doses climb is your prescriber's call; the dose list itself is in Zepbound doses.
Zepbound leaves the body slowly, but blood concentrations alone do not establish a symptom’s duration. The label puts its half-life at “approximately 5-6 days” [1], which helps describe drug exposure rather than a guaranteed side-effect recovery schedule.
Trial rates describe groups and cannot predict your reaction
Digestive side effects affected 56% of people at every Zepbound dose in the weight trials, against 30% on placebo [1]. That placebo number matters. Nearly a third of people taking a dummy injection also reported stomach symptoms, so the active-drug rate is not the same as the proportion caused solely by treatment. Randomized group differences inform risk; they cannot assign the cause of an individual symptom.
Stopping for side effects was less common than having them. Across the trials, 4.8%, 6.3% and 6.7% of people on 5, 10 and 15 mg stopped because of side effects, compared with 3.4% on placebo [1].
Injection-site reactions, fatigue and allergic reactions
The brand itself is profiled in Zepbound. Its common non-digestive side effects are injection-site reactions (6% to 8%), fatigue (5% to 7%) and allergic-type reactions (5%) [1]. Most of the allergic-type reactions in the trials were skin reactions, such as rash or itching.
Some people's immune systems make antibodies to tirzepatide, and the label reports more reactions in that group. Injection-site reactions occurred in 11.3% of people with anti-tirzepatide antibodies versus 1% without. Allergic-type reactions occurred in 6.2% versus 3% [1]. Those are associations in trial subgroups, not proof that antibodies explain an individual reaction or that routine antibody testing would resolve it. Report recurring reactions and act promptly on the serious-allergy warning signs below.
Hair loss is on the label, and it's tied to weight loss
Hair loss was reported by 4% to 5% on Zepbound versus 1% on placebo. It was far more common in women: 7.1% of women versus 0.5% of men on Zepbound. The label says hair loss reactions “were associated with weight reduction,” and no one on Zepbound stopped the drug because of it [1].
Dizziness, low blood pressure and a small heart-rate rise
Dizziness affected 4% to 5% on Zepbound, and low blood pressure 1.6% versus 0.1% on placebo [1]. Low blood pressure was more common in people already on blood-pressure medicines (2.2% versus 1.2%), and the label says it “also occurred in association with gastrointestinal adverse events and dehydration.” Average resting heart rate rose by 1 to 3 beats per minute.
Side effects people ask about that aren't on the label
Feeling cold, chills, joint pain, leg cramps and sexual side effects don't appear anywhere in Zepbound's prescribing information or Medication Guide. That isn't proof they never happen. The label does not explain every absent term or rule out an individual association. It includes both trial findings and reports after approval; frequency cannot be inferred from absence.
| Symptom | On the label? | Nearby facts the label does list |
|---|---|---|
| Feeling cold, chills | No | Fatigue 5% to 7%; low blood pressure 1% to 2% |
| Joint pain, body aches | No | None directly related |
| Leg cramps | No | Dehydration from vomiting or diarrhea is a listed risk |
| Sexual side effects | No | Birth control pills may work less well (see below) |
Full-text search of the Zepbound prescribing information and Medication Guide [1]. If you notice any of these, tell your prescriber, and you can report it to FDA's MedWatch program [2].
Tell your prescriber about new or troubling symptoms without assuming their cause. Severe, persistent or rapidly worsening symptoms warrant prompt assessment rather than waiting for a routine visit. For tirzepatide as a molecule, beyond the Zepbound brand, see tirzepatide side effects.
Serious side effects to know, and their warning signs
The label lists several serious warnings; they do not all have a known frequency or the same risk in every population. Each one has symptoms worth knowing, and the Medication Guide spells them out in plain words [1].
| Warning | How often in trials | What the Medication Guide says to watch for |
|---|---|---|
| Pancreatitis | 0.2% on Zepbound vs 0.2% on placebo (confirmed cases) | “severe pain in your stomach area (abdomen) that will not go away,” sometimes felt in the back. Stop Zepbound and call your provider right away |
| Gallbladder problems | Gallstones 1.1% vs 1%; inflammation 0.7% vs 0.2%; gallbladder removal 0.2% vs 0 | Upper stomach pain, fever, yellow skin or eyes, clay-colored stools |
| Kidney injury from dehydration | 0.5% vs 0.2% | Nausea, vomiting or diarrhea “that does not go away” |
| Serious allergic reaction | Severe reactions 0.1% vs 0 | Swelling of face, lips, tongue or throat; trouble breathing or swallowing; severe rash; fainting; very rapid heartbeat. Get medical help right away |
| Low blood sugar | 4.2% vs 1.3% in people with type 2 diabetes; 10.3% with a sulfonylurea | Dizziness, sweating, shakiness, confusion, blurred vision, fast heartbeat |
| Vision changes in type 2 diabetes | Not given as a rate | Any change in vision during treatment |
| Food in the lungs under anesthesia | Rare reports after approval | Tell every clinician you take Zepbound before surgery or sedation |
| Thyroid tumors (boxed warning) | Seen in rats; unknown in people | A lump or swelling in your neck, hoarseness, trouble swallowing, shortness of breath |
Rates from the label's pool of two weight-reduction trials unless noted [1].
One thing isn't a side effect but matters: Zepbound can make birth control pills less reliable. The label advises switching to a non-oral method, or adding a barrier method, “for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation” [1]. Questions about fluids and urination are covered for Mounjaro, the same molecule approved for diabetes, in does Mounjaro make you pee more.
Severe gastrointestinal reactions were reported in 1.7%, 2.5% and 3.1% of participants receiving 5, 10 and 15 mg, versus 1% on placebo. Zepbound is not recommended with severe gastroparesis. The label also lists postmarketing ileus, intestinal obstruction and severe constipation including fecal impaction. Voluntary reports cannot reliably establish their frequency or prove that the drug caused each case [1]. This distinction matters when comparing a trial percentage with an online report: they do not have the same denominator or evidentiary meaning.
The label's own answer to side effects is a slow climb, or a lower dose
Zepbound's label builds its dose increases around the stomach. Its stated reason is “to reduce the risk of gastrointestinal adverse reactions.” And if a maintenance dose isn't tolerated, it tells prescribers to “consider a lower maintenance dosage” [1]. Both are your prescriber's decisions, which is why ongoing side effects are worth reporting rather than enduring.
The Medication Guide adds one practical line: “It is important for you to drink fluids to help reduce your chance of dehydration. Tell your healthcare provider right away if you have nausea, vomiting, or diarrhea that does not go away” [1]. Other management decisions, including over-the-counter remedies, belong with your prescriber or pharmacist. Do not interpret hydration advice as sufficient care for severe or persistent symptoms.
The trial percentages describe branded Zepbound and cannot establish the safety profile of a particular compounded tirzepatide product. Compounded tirzepatide has additional quality and preparation risks, covered in is compounded tirzepatide safe. The molecule's broader profile is in tirzepatide, and if cost is part of your decision, see what Zepbound costs.